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Background: Targeted therapy of human cancers is an attractive approach and has been investigated with limited
success. We have developed novel cytotoxic agents for targeted therapy of human cancers based on the
extracellular cytotoxicity domain of CD178 (FasL) and the specificity offered by single chain antibodies (scFv) against
dominant human tumor Ag TAG-72 (cc49scFv) and TAL6 (L6scFv).
Results: The cc49scFv-FasLext is highly effective in in vitro killing of human TAG-72
+ Jurkat-Ras tumor cells with a
30,000 fold greater cytotoxicity as compared to soluble FasL (sFasL). On the other hand, L6scFv-FasLext only
increased cytotoxicity 500-fold as compared with sFasL against TAL6+ HeLa cells in in vitro assays. The high
specificity and strong cytotoxicity of cc49scFv-FasLext made it feasible to cure IP-implanted Jurkat-Ras tumors in
SCID mice.
Conclusion: Our study demonstrated that scFv-FasLext with a strong cytotoxicity against sensitive human tumor
targets may be useful as effective chemotherapeutic agents.Background
Targeted therapy of human cancers has been considered
by many investigators and remains an attractive ap-
proach to avoid side effects of cancer treatment. Anti-
CD95 (Fas) Ab that induces Fas+ tumor apoptosis
in vitro has been investigated as a potential reagent for
this purpose [1]. One approach to increase the specificity
of the killing is to link the FasL extracellular cytotoxic
domain (FasLext) with a tumor Ag specific single chain
Ab (scFv). Such fusion proteins may attract the binding
of FasLext only to tumor cells and selectively induce
apoptosis of cancer cells.
A study based on similar concept had been reported
in a mouse tumor model [2]. An scFv derived from anti-
fibroblast activation protein (FAP) Ab was fused with
FasLext. It was clearly demonstrated that such a fusion
protein did not induce liver toxicity [2]. Interestingly,
local treatment with the fusion protein against Fas+ can-
cer cells that had been transfected with FAP prevented
tumor growth in the skin whereas un-transfected tumor* Correspondence: rs3wn@virginia.edu
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reproduction in any medium, provided the orcells were marginally inhibited [2]. Apparently, the FAP-
transfected cancer cells continuously provided the
source that allowed aggregate formation of the fusion
protein such that strong cytotoxicity against the Fas+
cancer cells could be induced [2]. In another related
study, it was demonstrated that CTLA-4-FasLext recom-
binant protein did not display liver toxicity. It also did
not express cytotoxicity against Fas+ target cells in vitro
unless B7-bearing cells were added. Apparently, only
through forming FasL aggregate on the B7+ cells could
the toxicity be induced [3].
In contrast to the above studies, we generated two re-
combinant scFv-FasLext fusion proteins using scFv derived
from cc49 and anti-TAL6 mAb, which target human
tumor-associated glycoprotein (TAG-72) and tumor-
associated Ag L6 (TAL6), respectively [4,5]. As compared
with soluble FasL (sFasL), L6scFv-FasLext was 500-fold
more cytotoxic against TAL6+ HeLa cells and cc49scFv-
FasLext was 30,000-fold more cytotoxic against TAG-72
+
Jurkat lymphoma cells. The cc49- and L6- scFv-FasLext
fusion proteins serve as important reciprocal controls,
demonstrating the specificity and sensitivity of cytotoxicity
against Jurkat and HeLa cells respectively in vitro. In ani-
mal models, cc49scFv-FasLext cured Jurkat-Ras (Jurkat
cells transfected with human Ras oncogene) tumorstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the recombinant protein depending on TAG-72 and Fas
expression as well as high-sensitivity of the tumor to
cc49scFv-FasLext. Our study raises the possibility that cer-
tain human cancers may be highly sensitive to cc49scFv-
FasLext such that they may be treated with the bioactive
reagent.
Methods
Animals, cancer cells, and immunochemical reagents
The immune compromised SCID mice on BALB/c back-
ground (CBySmn.CB17-Prkdcscid) and Rag1-/- mice in B6
background (B6.129S7-Rag1tm1Mon/j) were obtained from
the Jackson Laboratories, Bar Harbor, Maine, USA. Anti-
TAG-72 (cc83) and anti-L6 mAb were provided by co-
author Dr. S. Roffler. All human cancer cells with the ex-
ception of Jurkat-Ras were obtained either from ATCC or
the tissue culture center of the University of Virginia. The
Jurkat-Ras cell line was kindly provided by Dr. D. Faller at
the Boston University School of Medicine. Experiments
involving animals were conducted in accordance with the
protocols approved by the Animal Care and Use Commit-
tee (ACUC) of the University of Virginia.
Plasmids
The plasmid p2c11-γ1-B7, containing 2c11scFv encoding
anti-mouse CD3ε chain, pLHCX-cc49-hβG, a construct
encoding cc49scFv, and pET22b-L6, a construct encod-
ing L6scFv, were prepared by Liao et al and Chou et al
[6,7]. pBluescript II KS-hFasL, a plasmid containing the
human FasL, was a gift from Dr. S. Nagata [8].
Construction of cc49scFv-FasLext and L6scFv-FasLext
The scFv-FasLext constructs were first assembled in a
pHook-based vector. This involved first making 2c11scFv-
FasLext from p2c11scFv-γ1-B7 construct by replacing the
γ1-B7 portion with FasLext. Subsequently, 2c11scFv was
replaced with cc49scFv and L6scFv.
To generate the pHook 2c11scFv-FasLext fusion protein
construct, the γ1-B7 portion of p2c11-γ1-B7 was replaced
with FasLext. The following primers were used to amplify
FasLext from pBluescript II KS-hFasL: 5
0- CGGACCAG
GACAAGTACAACTACAAGAAAAAAAGGAGCTGA
GG -30 and 50- TCTAGAATTCTCGAGTTAGAGCTTA
TATAAGCCGAAAAACGTCTG -30 using Hotstart PFU
Turbo (Stratagene), according to the manufacturer’s di-
rections. Subsequently, T4 polynucleotide kinase (New
England Biolabs) was used to blunt end the PCR product.
Afterward, Xho I was used to digest the PCR product and
the PCR mixture was electrophoresed. A band of about
460 bp was excised from the gel and purified using a
QIAEX II gel extraction kit (Qiagen). In a separate reac-
tion, pHook-scFv-γ1-B7 was digested with Sal I, filled inwith Polymerase Klenow Fragment, cut with Xho I, and li-
gated with the FasLext fragment.
To generate cc49scFv-FasLext and L6scFv-FasLext, the
2c11scFv fragment was excised from pHook 2c11scFv-
FasLext using Sfi I and Sal I restriction enzymes, and re-
placed with the PCR product coding for either the
cc49scFv or L6scFv digested with Sfi I and Sal I. The
primers used to amplify cc49scFv, L6scFv, and incorpor-
ate the Sfi I and Sal I restriction sites at either end were;
cc49FP50-TGCCATGGCCCAGCCGGCCCAGGTTCAG
TTGCAGCAGTCTGA-30 and cc49RP 50- TCCTGGTC
CGTCGACTCCGCTTCCTCCGCTTCCTTTCAGCAC
CAGCTTGGTCCCAG-30; L6FP: 50- ATAGGTTGCCA
TGGCCCAGCCGGCCATTGTTCTCTCCCAGTCTCC
AGCA -30 and L6RP 50- TCCTGGTCCGTCGACTC
CGCTTCCTCCGCTTCCGGATGAGGAGACTGTGA
GAGTGGT-30.
To obtain higher expression levels, the cc49scFv-FasLext
and L6scFv-FasLext expression cassettes were PCR ampli-
fied from the pHook based vectors using the following
common primers, digested with Xho I and Not I restriction
enzymes and cloned in the pBCMGSNeo vector at the
Xho I and Not I sites. BCMGXhoI FP 50- ATCGCCT
CTAATCTCGAGATGGAGACAGACACACTCCTGC
TA-30 and BCMGNotI RP 50- GGCCTCGACTCGCA
TGCGGCCGCTTAGAGCTTATATAAGCC GAA-30.
Generation of cell lines expressing the fusion proteins
Transfection of plasmids was performed using lipofec-
tamine (Invitrogen) or electroporation at 960 μF capaci-
tance and voltages of 270 mV, 280 mV, or 290 mV using a
BioRad Gene Pulser (BioRad). Ten million NIH-3T3 or
BW5147 cells were utilized for each transfection. Immedi-
ately after transfection, cells were grown in DMEM
(Invitrogen) containing 10% heat-inactivated FCS, vitamin
solution (Cellgro), 100 mM sodium pyruvate solution, and
penicillin-streptomycin-glutamine (Invitrogen). Two days
later, 0.6 mg/ml of G418 (Invitrogen) was added to cul-
tures and cells were allowed to adapt over a 2-week
period. Cells were then transferred to fresh media
containing 1 mg/ml of G418. Cell cultures were split as
necessary, while maintaining G418 concentrations. After
the mock transfected cells were dead, the mixtures were
cultured for an additional 2 weeks in media containing
G418. Subsequently, culture supernatants were collected
and screened for cytotoxic activity against A20 cells. Cell
populations whose supernatant expressed cytotoxicity
were expanded for subsequent use in assays. Cells from
wells with strongly cytotoxic supernatants were adapted to
normal culture medium and expanded for further studies.
Flow cytometric analysis
Half a million cells were stained for Fas expression using
PE-DX2 anti-Fas (Pharmingen) mAb, and with PE-
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of L6 and TAG-72 was done using a two-step staining.
L6 mAb, IgG2a isotype control (G155-178, Pharmingen),
cc83 ascites fluid (a second generation mAb made against
purified TAG-72) [5], and heat-inactivated BALB/c serum
were used first, followed by washing and staining with
fluorescent secondary Ab. For two-step staining using
scFv-FasLext, 1 ml of respective transfected cell culture
supernatant was added to each cell pellet. Cells were incu-
bated on ice in the dark for 45 minutes. Cells were rinsed
2 times in PBS and supernatants were removed. Cells were
then stained with FITC- or PE-goat anti-mouse IgG
(Southern Biotech), PE-Alf 1.2 anti-FasL (Caltag), and PE-
mouse IgG2a isotype control (Caltag) secondary Ab. Cells
were incubated on ice in the dark for 45 minutes, rinsed 2
times with PBS, and then fixed in 2% paraformaldehyde.
Samples were analyzed using CellQuest and a Becton-
Dickenson flow cytometry machine.Immunoblot
40 μl of cell supernatants or media were loaded onto a
15% polyacrylamide gel using Laemmli buffer. A FasL re-
combinant protein corresponding to the human FasLext
was used as a positive control (Santa Cruz Biotechnology)
(data not shown). Proteins were resolved at 40 mA and
transferred at 150 V for 75 minutes onto PVDF mem-
branes using a BioRad MiniProtean II system (BioRad).
Membranes were then blotted with rabbit polyclonal
anti-HA or rabbit polyclonal anti-FasL (C-20) (Santa Cruz
Biotechnology) followed by HRP-conjugated donkey anti-
rabbit Ab [HRP] (Amersham Biosciences). Bound HRP
were exposed to ECL reagents (Amersham Biosciences) and
results were recorded using X-OMATAR film (Kodak).Size exclusion analysis
Culture supernatants were fractionated using a Millipore
molecular membrane filtration apparatus that separates
molecules based on their sizes above or below 300 kDa.
The volumes of both the “Flow-through” and “Retentate”
fractions were brought to original volume with fresh cul-
ture medium and examined for cytotoxicity against A20
target cells.Quantification of FasL
The scFv-FasLext concentration in supernatants was deter-
mined using a commercial kit for sFasL (Oncogene Sci-
ence). The molecular mass of sFasL was assumed to be
26 kDa based on gene sequence data. The molecular mass
of the fusion proteins was estimated to be 54 kDa. A stand-
ard curve was generated. Absorbance values of samples
that fell within the linear range of the standard curve were
used to determine the original sample concentrations.Cytotoxicity assays
Cytotoxicity assays against various target cells were
conducted as previously described. Target cells (2×104), la-
beled with Na2
51CrO4 (New England Nuclear), were cul-
tured with various doses of Jo2 mAb (BD Pharmingen) or
culture supernatant in 0.2 ml in individual wells of a 96-
well plate for 5 hours in a 37°C, 10% CO2 incubator [9,10].
Supernatants were removed and radioactivity (cpm) was
determined using an LKB-Wallac gamma counter
(Perkin-Elmer). Background release was determined by
culturing cells alone. Cytotoxicity is expressed as% specific
51Cr release, which is determined by the formula: 100% ×
(experimental release–background release)/(total cpm -
released by 0.5% NP − 40–background release). Assays
were carried out in duplicate and the experiment was re-
peated three times. For adherent human cancer cell lines
such as HeLa, LS-174 T, and several breast cancer cell
lines, cells in 96-well plate were either treated overnight
with IFN-γ (100 ng/ml) or left untreated followed by the
addition of the cytotoxic proteins. The standard MTT
(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) (Sigma) assays were conducted 18 hours after
IFN-γ treatment [11]. In some experiments, cytotoxicity
assays were conducted in the presence of inhibitors such
as Alf 1.2 anti-FasL, NOK-1 anti-FasL [12], cc83 anti-TAG
-72 [5] or anti-L6 [6] mAb with isotype included as appro-
priate controls.
Treatment of cancer cells in vivo
We could not grow Jurkat cells in SCID and Rag1-/- mice
using (30-50) ×106 cells per IP injection even at 4 months
after implantation. However, tumor growth was readily
achieved by using Jurkat-Ras cells. This dose was used for
the treatment studies with cc49scFv-FasLext. SCID mice
implanted IP with Jurkat-Ras cells and not treated with
the cc49scFv-FasLext fusion protein usually died within
5 weeks.
Two days after tumor implantation, scFv-FasLext con-
taining supernatant (1 ml for cc49scFv-FasLext containing
approximately 2 μg FasL equivalent, based on ELISA
assay) was injected IP into the peritoneum every other day
for as long as 4 weeks or until the mice died. In some ex-
periments, the first injection of cc49scFv-FasLext was ad-
ministered at 6 days after tumor implantation.
Results
Derivation and immunological characterization of scFv-FasLext
We transfected several cell lines with the recombinant
cc49scFv-FasLext and L6scFv-FasLext constructs and used
limiting dilution technique to obtain the clones that pro-
duced the highest cytotoxicity against the A20 tumor
cells, which express Fas Ag and are sensitive to sFasL-
mediated cytotoxicity [12]. The selected clones were
then gradually adapted to growth in normal culture
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Figure 1A, culture supernatants for two clones, cc49scFv-
FasLext and L6scFv-FasLext transfectants, but not the su-
pernatants from BW5147 and 3T3 (see legend), were
shown to have strong cytotoxicity against the A20 target
cells. In addition, culture supernatant of these clones
adapted to grow in serum-free media was also strongly
cytotoxic (data not shown). The results showed that the
cytotoxic components were derived from the transfected
recombinant genes, i.e., scFv-FasLext.Biochemical characterization of scFv-FasLext
We determined the molecular sizes of the cytotoxic com-
ponents secreted by the scFv-FasLext transfected cells by
molecular membrane filtration through a 300 kDa
Millipore filter. As shown in Figure 1B, the large propor-
tion of Fas-dependent cytotoxicity was present in the
“Retentate” of the L6scFv-FasLext whereas the great major-
ity of cytotoxicity was present in the “Flow-through” ofFigure 1 Immunochemical characterization of cc49scFv-FasLext and L6
using culture supernatants from cc49scFv-FasLext and L6scFv-FasLext transfe
and 3T3 had no detectable cytotoxicity against A20. (B and C) Membrane
molecular filtration was used as described in Methods. Flow-through and “
readjusted to original volume and tested for cytotoxicity against A20. (D) P
for the presence of fusion proteins. Dilutions used were 1000 fold for anti-H
conjugated anti-rabbit Ab.cc49scFv-FasLext supernatant (Figure 1C). The result indi-
cated that individual scFv-FasLext form different levels of
multimeric structures. The cytotoxic activities in the re-
spective fractions were verified by Western blotting to cor-
respond to the scFv-FasLext fusion proteins (not shown).
Western blotting analyses of the culture supernatants
from both clones using polyclonal anti-HA for scFv and
anti-C20 FasLext Ab demonstrated that the scFv-FasLext
fusion proteins expressed the expected molecular size
under denaturing and reducing conditions (Figure 1D).Targeting cancer Ag specifically increases cytotoxicity
against the Ag-bearing human cancer cells
We chose a positive way to demonstrate the strong asso-
ciation between TAG-72 and Fas for the increase in
cytotoxicity of cc49scFv-FasLext. TAL6 and TAG-72 that
are broadly expressed on a variety of human cancer cell
lines were examined for their potential as appropriate
targets for scFv-FasLext. The expression of Fas, TAL6,scFv-FasLext. (A) Cytotoxicity was detected against A20 target by
cted BW5147 and 3T3, respectively. Culture supernatants from BW5147
filtration analysis of cytotoxic materials: A 300 kDa membrane
Retentate” of cc49scFv-FasLext (B) and L6scFv-FasLext (C) samples were
olyclonal rabbit anti-FasL (C-20) and rabbit anti-HA were used to probe
A, 1000 fold for anti-C-20, and 4000 fold for horseradish peroxidase-
Figure 2 Expression of cancer Ag and Fas on various human cancers. (A) HeLa, 231, DKBK3, 468, and MCF7 cell lines were analyzed by flow
cytometry for Fas, TAL6, and TAG-72 expression: left panels (Fas expression); center panels (TAL6 expression); right panels (TAG-72 expression).
All positive stains were indicated by red lines. Background staining was indicated by green or gray lines. (B) Expression of Fas (red line-left panel),
TAL6 (red line-middle panel) and TAG-72 (dark blue-right panel) on Jurkat cells. Jurkat cells are Fas+TAL6-TAG-72+.
Chan et al. Journal of Biomedical Science 2013, 20:16 Page 5 of 9
http://www.jbiomedsci.com/content/20/1/16and TAG-72 on tumor cells was determined by Flow cy-
tometry (Figure 2). Among a half dozen human cancer
cells, significant expression of these Ag are observed al-
though with great variability. Among these cancer cell
lines, HeLa (TAL6+Fas+) was the most sensitive target to
L6scFv-FasLext and Jurkat (TAG-72
+Fas+) was the mostFigure 3 Increase of sensitivity of human cancer target cells bearing
respectively. The cytotoxicity against A-20 and Jurkat targets were conduc
targets was conducted in 24-hour MTT assays. Please note that x-axis scalesensitive one to cc49-FasLext (Figure 3 below). Human
cancer line LS-174T also expressed both Fas and TAG-
72 [5] but they were much less sensitive than Jurkat to
cc49-FasLext (data not shown). In all cases, we noticed
that increased sensitivity toward scFv-FasLext required
the strong expression of both tumor Ag and Fas.TAG-72 or TAL6 toward cc49-FasLext and L6scFv-FasLext,
ted with 5-hour 51Cr release assays. The cytotoxicity against HeLa
of panel C is on a pM scale.
Figure 4 Inhibition of cytotoxicity of fusion proteins by anti-
FasL, anti-TAG-72, and anti-L6 mAbs. Cytotoxicity against HeLa
cells and cytotoxicity against Jurkat cells were shown in 2A and 2B,
respectively. NOK-1 (2 μg/ml) and Alf 1.2 (2 μg/ml) anti-FasL were
used as inhibitors against cc49scFv-FasLext (0.8 nM) and L6scFv-FasLext
(3.2 nM), respectively. Both strongly inhibited the cytotoxicity. In
contrast, cc83 (5 μg/ml) failed to inhibit cytotoxicity against Jurkat cells
whereas anti-L6 (5 μg/ml) only inhibited 30% of the cytotoxicity
against HeLa cells caused by their respective fusion proteins.
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control for scFv-FasLext for Fas-mediated cytotoxicity with-
out the tumor Ag influence because mouse A20 expresses
only Fas but not the human TAG-72 nor TAL6. The cul-
ture supernatants from L6scFv-FasLext and cc49scFv-
FasLext showed comparable cytotoxicity against the
A20 target (Figure 3A). In addition, both scFv-FasLext
were more cytotoxic to A20 than sFasL. HeLa cells
(TAL6+TAG72-Fas+) were found to be 500-fold more
sensitive to L6scFv-FasLext than sFasL (Figure 3B)
whereas Jurkat cells (TAL6-TAG-72+Fas+) were 30,000
times more sensitive to cc49scFv-FasLext than sFasL
(Figure 3C). In addition, L6scFv-FasLext was significantly
more cytotoxic against HeLa cells as compared to
cc49scFv-FasLext (Figure 3B). Conversly, cc49scFv-FasLext
displayed far more enhanced cytotoxicity against Jurkat
cells as compared to L6scFv-FasLext (Figure 3C). The re-
sults clearly demonstrated that the increase in Fas-
mediated cytotoxicity of scFv-FasLext required targets
bearing the cognate tumor Ag.
The tumor and Fas Ag that react with the fusion pro-
teins was determined by inhibition of cytotoxicity. As
shown in Figure 4, anti-human FasL mAb (NOK-1 or
Alf 1.2) strongly inhibited the killing of HeLa cells by
L6scFv-FasLext and of Jurkat cells by cc49scFv-FasLext, re-
spectively. Although the ability of anti-L6 mAb to inhibit
HeLa killing by L6scFv-FasLext was moderate, the ability
of cc83 to inhibit the killing of Jurkat by cc49scFv-FasLext
was minimal. It is important to note that inhibition of
cytotoxicity by anti-FAP and anti-CTLA-4 was not
reported [2,3]. This condition may be caused by the in-
creased binding sites against tumor Ag relative to FasLext
on the recombinant proteins. The cc49scFv-FasLext also
had a 3-fold increase in tumor Ag binding sites due to the
ability of FasLext to form trimers. In addition, the ex-
tremely strong cytotoxicity suggests a strong expression of
tumor Ag such that inhibition of cytotoxicity was difficult
to achieve. Other possibilities uniquely associated with
Jurkat cells are addressed in the “Discussion”.
Treatment to increase sensitivity of TAL6+Fas+ cells to
L6scFv-FasLext
Because HeLa cells only showed a 500-fold increase in
sensitivity toward L6scFv-FasLext relative to sFasL, we
tried increasing the sensitivity of L6scFv-FasLext against
TAL6+Fas+ target cells. IFN-γ has been shown to in-
crease the sensitivity of cancer cells to Fas-mediated
apoptosis [13,14]. To see if treatment with IFN-γ in vitro
would increase their sensitivity the TAL6+Fas+ target cell
lines were treated with IFN-γ as described in “Methods”.
Although, the result showed that such treatment increased
tumor cell sensitivity by 3-5 folds toward L6scFv-FasLext
(Table 1), HeLa remained the most sensitive cancer cells
examined. In in vivo experiments L6scFv-FasLext culturesupernatant administered at various doses was unable to
protect SCID mice implanted with HeLa tumors due to
insufficient increase in cytotoxicity and therefore, was not
studied further (data not shown).
Treatment of TAG-72+Fas+ human cancer cells in SCID
mice with scFv-FasLext
We established tumor models in SCID mice to deter-
mine whether cc49scFv-FasLext fusion protein, which ex-
presses extremely high cytotoxicity against Jurkat cells,
is therapeutic. Jurkat cells do not form tumors in SCID
Table 1 IFN-γ treatment enhances the sensitivity of
cancer cells to L6scFv- FasLext mediated apoptosis
Target cells % Specific killing of 104 cells/well by L6scFv-FasLext
(μl/well)
30 μl 10 μl 3 μl 1 μl 0.3 μl 0.1 μl
HeLa 84 80 64 32 4 3
IFN-γ-HeLa 87 85 62 60 46 24
468 58 53 41 11 −5 −3
IFN-γ-468 83 81 79 69 35 17
DKBK3 21 13 11 13 10 11
IFN-γ-DKBK3 78 66 44 31 17 7
Breast cancer cells were sensitized by IFN-γ in vitro. Under the cytotoxicity
assay condition, IFN-γ (100 ng/ml) enhanced 3-10 folds of the target
susceptibility to L6scFv-FasLext.
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50×106 cells IP. However, the Jurkat-Ras cells were able
to form tumors in SCID mice. The in vitro cytotoxicity
of Jurkat-Ras did not differ from Jurkat (data not
shown). We transferred 40×106-50×106 Jurkat-Ras cells
in SCID mice, resulting in tumor growth and death at 4-
5 weeks after transfer. At 2-6 days after cancer cell
transfer, we started treatment by IP injection with 1 ml
of cc49scFv-FasLext-containing culture supernatant every
other day. Control groups were injected with culture
medium of BW5147 cells. Remarkably, treatment of
Jurkat-Ras tumor transplants with cc49scFv-FasLext-
containing culture supernatants protected the mice from
mortality (Table 2). The great majority of the recipients
remained alive and healthy at 1-2 months after treat-
ment whereas tumor growth was evident in control
groups at this time. Tumor growth was confined in the
peritoneum with individual colonies, some of which
were attached to the outer surface of liver, spleen, stom-
ach, and intestinal walls. The treated mice were free of
any visible tumor cells. They remained healthy for an-
other two months after the treatment was stopped.
Eradication was accomplished since these mice remained
healthy for an additional 14 weeks (Table 2). The data
demonstrate a successful eradication of Jurkat-Ras
tumor cells transplanted in SCID mice by targeted ther-
apy using cc49scFv-FasLext fusion protein.Table 2 Highly cytotoxic cc49scFv-FasLext eradicated Jurkat-R
Cells injected on day 0 Treatment begins on # mice treated
(40-50)×106 Jk-Ras Control Day 1-2 7
(40-50)×106 Jk-Ras Test Day 1-2 8
20×106 Jk-Ras Control Day 6 4
20×106 Jk-Ras Test Day 6 5
aSCID mice (>14 weeks old) of both sexes were transferred by IP injection of Jurkat
injection of cc49scFv-FasLext-containing supernatants (2 μg/ml) or concentrated L6s
bTwo months after the end of the treatment, the survived mice still lived without a
was observed when survived mice were euthanized later.Discussion
The present study suggests that using scFv-FasLext fu-
sion protein as a therapeutic agent against human can-
cers is feasible only if the target tumor is extremely
sensitive to the scFv-FasLext –mediated cytotoxicity, such
as the case for cc49scFv-FasLext mediated cytotoxicity
against Jurkat cells. However, other than Jurkat-Ras, we
have not found a second commonly used human cancer
cell line that displays such sensitivity to cc49scFv-FasLext
and can be cured in an animal model. In the vast reper-
toire of tumor diversity in human cancers, highly sensi-
tive tumors like Jurkat cells may exist and as such may
be sensitive to cc49scFv-FasLext. In this respect, various
cancer cells present in repositories that express Fas and
TAG-72 should be examined for their sensitivity to
cc49scFv-FasLext. Even if a small fraction of the TAG-72
+
human tumors were found to be nearly as sensitive as
Jurkat, it would be significant that the cc49scFv-FasLext
could completely eradicate the cancer cells. Moreover, our
study also raises the possibility in using scFv-FasLext in
combination therapy in which tumor cell sensitivity to
scFv-FasLext can be enhanced by commonly used cancer
treatment protocols.
Intuitively, it is difficult to understand how such a dra-
matic increase in cytotoxicity against Jurkat cells was
observed when cc49scFv was fused with FasLext. A
30,000-fold increase in cytotoxicity is not easily com-
prehended simply by adding a co-operative ligand to aid
for binding. Several possibilities may explain this observa-
tion. First, only Jurkat among many cancers displayed
such a high susceptibility, suggesting that high sensitivity
to FasL-mediated apoptosis is a property characteristic of
the Jurkat target. A recent study has shown that Fas-
mediated apoptosis in Jurkat cells triggers rapid release of
ATP via pannexin1 channels, leading to an ATP-
dependent purinergic receptor-mediated death [15].
Higher order structures formed due to aggregation of scFv
component [16], so as to form scFv dimers/trimers of
FasLext trimers could have enhance the cytotoxicity of
FasLext moiety, as evidenced by higher cytotoxicity of both
cc49 and L6 -scFv-FasLext on A20, HeLa and Jurkat cells
compared to sFasL (Figure 3). Previous studies have
shown that controlled cross-linking of sFasL trimersas cancer in SCID micea
Tumor incidence # tumor-free mice at the end of the treatmentb
6 at 4-6 wk later 1
0 at 4-6 wk later 8
4 at 4-6 wk later 0
1 at 4-6 wk later 4
-Ras (Jk-Ras) or HeLa at day 0. Treatment started at indicated times by IP
cFv-FasLext (5-10 μg/ml) as described in the “Methods”.
ny indication of toxicity induced by the treatment. Normal liver appearance
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http://www.jbiomedsci.com/content/20/1/16increased the cytotoxicity by over a 1000-fold as com-
pared to uncross-linked sFasL, a property which is also ap-
plicable to soluble TRAIL and other members of the TNF
super-family ligands [17]. Second, The unique multimeric
structure of cc49scFv-FasLext (each Fas binding unit con-
tains 3 TAG-72 binding sites) may allow more efficient
binding to Jurkat TAG-72 Ag to outcompete anti-TAG-72
mAb. This will also add to the sensitivity of Jurkat to
cc49scFv-FasLext cytotoxicity and resistance to cc83-
mediated inhibition. Third, several TAG-72+ tumors in-
crease their TAG-72 expression (10-100 folds) after
implanting in athymic mice further leading to increased
sensitivity of Jurkat-Ras tumors to cc49scFv-FasLext
in vivo [2]. Fourth, the great majority of TAG-72 has a
molecular size of ≥106. Although TAG-72 has been well
established as the target Ag for cc49, high TAG-72 or
TAG-72-related target sites that are reactive to cc49scFv-
FasLext may be present on Jurkat since the reactive epi-
topes on Jurkat cells have not been characterized. These
sites may be revealed or modified by the post-translational
modifications of the TAG-72 [6].
Liver has been shown to be a target with lethal out-
come when mice were treated with anti-Fas mAb Jo2
[2]. This lethal effect was originally attributed to the tox-
icity of hepatocytes. We demonstrated that FcRII knock-
out mice are resistant to Jo2 treatment [18]. In addition,
anti-Fas mAb lacking FcRII binding activity also failed to
induce lethality [18]. Moreover, sFasL was extremely inef-
fective in inducing lethality due to its inability to form
aggregates on the target cells that lacked FcRII. Our study
suggested that FcRII-expressing sinusoid endothelial cells
in the liver are the real target for FcRII-dependent, Jo2-
mediated lethality, which cannot be induced with scFv-
FasLext. The scFv-FasLext lacks FcRII binding activity and
bears a ligand for tumor target Ag that selectively en-
hances binding to the cancer targets with minimal non-
specific cytotoxicity against Fas-expressing normal cells
that lack scFv targeted Ag.
There are potentially several ways to enhance the use
of scFv-FasLext for therapy. First, any existing protocols
for cancer therapies are likely to make the tumor target
cells more sensitive toward the cytotoxicity of the scFv-
FasLext. Second, increase in Fas expression levels on
target cells are often observed under various in vivo con-
ditions. Amongst them, activation of cells and induction
by cytokines such as IFN-γ almost always enhances Fas
expression levels. Others have claimed that IFN-α or
IFN-γ could induce higher expression of cancer Ag
[19,20]. Our studies on many tumor cells cultured in the
presence of IFN-γ only enhanced the cytotoxicity expres-
sion by 3-fold in a single in vitro treatment within 36 -
hours (pretreatment and cytotoxicity times), a level that
may be helpful but not very effective. Additional studies
are needed to determine if modulation of TAG-72 andTAL6 may be achieved to help the therapeutic effect of
the cc49scFv-FasLext and L6scFv-FasLext, respectively.
Conclusions
Our studies demonstrate the reciprocal specificity of
cc49scFv-FasLext and L6scFv-FasLext reagents and strongly
suggest that targeted therapy of human cancers with
FasLext based reagents is feasible, provided that the target
antigen is expressed on the cancer cells and that the tu-
mors are highly susceptible to FasLext. Hematopoietic can-
cers are attractive targets due to their likelihood of FasLext
sensitivity. The possibility of the use of interferons for
modulation of tumor antigen expression and increase in
susceptibility to L6scFv-FasLext -mediated cytotoxicity of-
fers additional strategies. The eradication of Jurkat-Ras
tumors with cc49scFv-FasLext without hepatic toxicity
warrants the screening of human hematopoietic cancer re-
positories for TAG-72 and Fas expression and their subse-
quent curability with this reagent.
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